echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clinical Nutrition: Body composition parameters can predict the prognosis of locally advanced gastric cancer patients after receiving neoadjuvant therapy

    Clinical Nutrition: Body composition parameters can predict the prognosis of locally advanced gastric cancer patients after receiving neoadjuvant therapy

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Patients with gastrointestinal tumor surgery often suffer from sarcopenia and visceral fat obesity, and body composition characteristics affect the prognosis of many cancers; body composition is locally advanced after neoadjuvant therapy (NT)The role of gastric cancer (LAGC) in patients has not been well studied.
    Therefore, this study aims to measure body composition in patients with locally advanced gastric cancer after neoadjuvant therapy to predict their disease prognosis
    .

     Patients with gastrointestinal tumor surgery often suffer from sarcopenia and visceral fat obesity, and body composition characteristics affect the prognosis of many cancers; body composition is locally advanced after neoadjuvant therapy (NT)The role in patients with gastric cancer (LAGC) has not been well studied,Stomach cancer

     

    Researchers performed related examinations on 213 patients in southern China, all of whom were LAGC patients who underwent post-NT gastrectomy
    .


    In addition, external verification was performed on 170 patients from western China and 77 patients from Italy


    diagnosis

     

    In general, all patients did not have any significant changes in body composition parameters after receiving NT
    .


    The pre-NT skeletal muscle radiodensity (SMD) and SMI changes (ΔSMI) were significantly reduced in patients with poor response.


     

    This study confirmed that for LAGC patients, SMD and ΔSMI levels before NT treatment can accurately predict the pathological response after NT
    .


    SMI loss >1.


    This study confirmed that for LAGC patients, SMD and ΔSMI levels before NT treatment can accurately predict the pathological response after NT


     

    Original source:

    Jian-Xian Lin.


    Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.